Permanent record
RIR-2039 · Logged 13 July 2026
Integrating Microbiome-Targeted Interventions into Clinical Management Protocols for Chronic Kidney Disease Patients
This research explores the gut–kidney axis to identify novel therapeutic targets for chronic kidney disease. It evaluates the efficacy of microbiome-based interventions like prebiotics and synbiotics in clinical settings.
In plain words
Can changing the bacteria in the gut help people with chronic kidney disease? This study would test treatments such as prebiotics and synbiotics in patients at stage 3 to 4, looking for a non-invasive way to slow the disease.
Primary research question
Can microbiome-targeted interventions effectively modulate harmful metabolites to improve clinical outcomes in chronic kidney disease patients?
Knowledge gap
What remains worth asking
The source suggests that the gut–kidney axis is a promising therapeutic target; it remains useful to test the clinical efficacy of specific synbiotic interventions in controlled trials.
Potential contribution
Why it may matter
Targeting the microbiome may provide a novel, non-invasive approach to managing chronic kidney disease progression.
Academic placement
Academic fields and topic tags
Study frame: Patients with stage 3-4 chronic kidney disease. · Method signals: Clinical Trial, Multi-omics Analysis, Systematic Review
Possible study pathways
One question, different levels
Research master’s
Translational research in microbiome-based therapeutic interventions.
Doctoral
Mechanistic investigation of the gut-kidney axis and clinical trial design.
- originality
- Moderate
- methodology
- Advanced
- Data access
- Moderate
- ethics
- Advanced
Quality and audit
85/100 quality
Safeguard-based audit was not recorded under the prior standard.
- Requires clinical trial infrastructure.
- High ethical requirements for patient intervention studies.
- Open-access scholarly source and DOI metadata verified
This older record can be checked against the current standard on request. It changes only if every academic gate and independent safeguard passes.
Sign-in required · uses one AI creditProvenance
Research Idea curation
- DOI and bibliographic metadata independently resolved
- Open-access status verified
- The accessible abstract explicitly states the future-research direction
The public contributor code contains no name or account email.
APA 7 source
Alobaidi, S. (2025). The gut–kidney axis in chronic kidney disease: mechanisms, microbial metabolites, and microbiome-targeted therapeutics. Frontiers in Medicine, 12, Article 1675458. https://doi.org/10.3389/fmed.2025.1675458
Abstract (explicit future-research recommendation)
Open source ↗